a contractile phenotype to a proliferative and synthetic phenotype. 2,3 However, mounting evidence indicated that SMLCs were of recipient origin, 4-6 and Tang et al 7 proved that mature medial SMCs could not dedifferentiate to entry cell cycle. Alternatively, a few studies have demonstrated that circulating bone marrow-derived cells (BMDCs) infiltrate the intima and express smooth muscle markers, such as α-smooth muscleactin. Therefore, SMLCs in the neointima likely differentiated from BMDCs. 8,9 However, Daniel et al 4 investigated the fate of enhanced green fluorescent protein (EGFP)-labeled BMDCs in a wire-induced injury model, and no highly differentiated SMCs markers were detected in EGFP + cells. BMDCs accumulated in the neointima and began to consistently decrease during the transient inflammatory response after vascular injury. 4 Iwata et al 10 also demonstrated that bone marrow cells
T he acute rejection of solid organ transplants has been effectively controlled with the development of immunosuppressive therapy; however, transplant arteriosclerosis (TA) remains a major obstacle to long-term survival. TA is characterized by a diffuse, concentric vascular neointimal hyperplastic lesion composed of smooth muscle-like cells (SMLCs) and an associated extracellular matrix. 1 Most neointima cells are similar to medial smooth muscle cells (SMCs) in appearance; nevertheless, there are important functional differences between these cells, and thus, neointima cells are generally labeled smooth muscle-like cells.
There are competing theories that explain the excessive accumulation of SMLCs and the origin of these cells. The previously accepted opinion was that neointimal SMLCs were derived from medial mature SMCs, which dedifferentiate from expressed monocyte/macrophage markers but not smooth muscle-myosin heavy chain (SM-MHC), the definitive marker of SMCs. BMDCs adhesion and extravasation into the vessel wall are the initial stage of neointimal hyperplasia, which is followed by the migration and proliferation of SMLCs in the neointima. 11 Recent evidence implicates the presence of several types of resident SMC-related vascular progenitors in vessels. [11] [12] [13] [14] [15] A small population of SM-MHC-negative, multipotent vascular stem cells were isolated in the tunica media, and these cells contributed to the neointimal hyperplasia instead of the medial SMCs. 7 Hu et al 16 reported abundant stem cell antigen-1 (Sca-1) + progenitor cells in the adventitia that differentiated into SMLCs and contributed to the progression of atherosclerosis of the vein graft. It has been demonstrated that certain chemokines expressed by BMDCs in neointimal regions could recruit adventitial vascular progenitor cells into the neointimal lesions. 10, [17] [18] [19] Thus, it is hypothesized that a local decrease in the BMDC-derived chemokine accumulation might attenuate the pathogenesis of TA.
MicroRNAs (miRNAs) comprise a family of noncoding oligonucleotides ≈22 nucleotides in length. 20 miRNAs are important regulators of chemokines that modulate inflammatory processes during the initiation and progression of atherosclerosis. 21, 22 This study demonstrated that microRNA-155 (miR-155) promoted the neointima hyperplasia during TA by regulating BMDC function. MicroRNA-155 plays a key role in sustaining the concentration gradient of monocyte chemoattractant protein 1 (MCP-1) between the intima and the adventitia, which is essential for the directional migration of the resident smooth muscle progenitor cells (SMPCs) of the adventitia.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

miR-155 Is Significantly Upregulated in the Neointima of TA
Segments of thoracic aorta from BALB/c donors were interposed into the abdominal aorta of C57BL/6 male mice, and allograft neointimal lesion samples were screened using miR-NAs microarrays 8 weeks later to investigate the miRNAs expression profile in TA. The isografts were used as controls. After excluding the miRNAs with low signals (signal <500), we observed the decreased expression of 56 miRNAs and increased expression of 49 miRNAs (Tables I and II in  the online-only Data Supplement) . We selected 23 miR-NAs, including miR-155, miR-122, and miR-196a, that had P values <0.01 and changes in expression levels of >3-fold. For further studies, the expression levels of miR-155, miR-122, and miR-196a were quantified by reverse transcriotionpolymerase chain reaction (RT-PCR) in neointima lesions at 2 and 4 weeks during the pathogenesis of TA. miR-155 was also strongly upregulated in the lesions compared with the isografts; however, there were no significant changes in the expression levels of miR-122 and miR-196a during the early stages ( Figure I in the online-only Data Supplement).
miR-155 Promotes Neointima Hyperplasia of TA Via Regulation of the Function of BMDCs
Segments of thoracic aorta from the BALB/c donors were transplanted into miR-155 −/− and miR-155 +/+ recipients, and the grafts were harvested 8 weeks later to investigate the effect of miR-155 in TA. The miR-155 −/− recipient group exhibited a significant reduction in neointimal hyperplasia by 8 weeks compared with the miR-155 +/+ group ( Figure 1A ). Then the bone marrow (BM) cell population of the miR-155 +/+ mice were repopulated with the BM cells from the miR-155 −/− mice (and vice versa); these mice were used as aorta transplantation recipients to further investigate the effect of miR-155 on BMDCs and resident non-BMDCs. miR-155 +/+ mice transplanted with miR-155 +/+ BM cells were used as controls. Recipients harboring miR155 −/− BM cells exhibited an obvious reduction in neointimal hyperplasia compared with the other 2 groups after 8 weeks. There was no significant difference in the intima/media (I/M) ratio between the 2 groups harboring miR155 +/+ BM cells ( Figure 1B and 1C). These results indicated that a miR-155 deficiency in BMDCs, but not in local non-BMDCs, alleviated neointima hyperplasia.
BMDCs Do Not Differentiate into SMLCs
We used chimeric C57BL/6 mice transplanted with EGFP transgenic BM cells as aorta transplantation recipients to precisely locate BMDCs and to investigate their roles during the pathogenesis of neointima hyperplasia in TA. EGFP signals from BMDCs were detected in the grafts as early as 24 hours after transplantation ( Figure II in the online-only Data Supplement). The number of EGFP + cells in the grafts culminated 2 weeks after transplantation and subsequently began to gradually decrease ( Figure IIIA and IIIC in the online-only Data Supplement).
The smooth muscle lineage marker was used to determine whether these EGFP + cells differentiated into SMLCs. SM-MHC was chosen as a definitive marker in our study because α-smooth muscle-actin is also detected in macrophages in inflammatory environments, with the exception of SMCs. 4 Consistent with previous reports, we did not find any EGFP + cells that expressed SM-MHC during the early or advanced stages of TA 10 ; however, nearly all of these cells expressed macrophage surface markers, such as CD68 ( Figure 2 ). 
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Resident SMPCs Accumulate in the Neointima After the BMDCs Aggregated in the Grafts
There is no supportive evidence that BMDCs contribute to neointima hyperplasia by differentiating into SMLCs.
Therefore, we used EGFP mice harboring C57BL/6 BM cells as aortic transplantation recipients and examined whether the SMLCs were derived from resident cells. A population of non-BM-derived EGFP + cells was detected in the neointima and adventitia of grafts during the early stage, which rapidly increased and plateaued in the neointima within 2 to 4 weeks ( Figure IIIB and IIID in the online-only Data Supplement). During the advanced stage of TA, the EGFP + cells comprised the majority of neointima cells, and the quantity of cells remained relatively stable both in the neointima and the adventitia ( Figure IIIB and IIID in the online-only Data Supplement). We also used SM-MHC as a smooth muscle marker to define these resident cells and found that few of the EGFP + cells located in the adventitia expressed SM-MHC between the early and the advanced stage ( Figure 3A ). However, most of the EGFP + cells in the neointima expressed SM-MHC 8 weeks after transplantation ( Figure 3A) . The SM-MHC mRNA level of the neointima was measured using RT-PCR, and the expression of SM-MHC mRNA increased at different times after transplantation ( Figure IV in the online-only Data Supplement). We then used an early differentiated marker for SMCs, SM-22α, to identify these cells. Almost all of the EGFP + cells were also positive for SM-22α at 2 and 8 weeks after the transplantation ( Figure 3A ).
Figure 3.
Immunofluorescence of aortic allografts from enhanced green fluorescent protein (eGFP) + recipients harboring C57BL/6 bone marrow (BM) cells second and eighth week after aortic transplantation. A, eGFP + cells coexpressed smooth muscle (SM)-22α at second and eighth week, while they were SM-myosin heavy chain (MHC) negative at second week but expressed SM-MHC in the neointima at eighth week (5-6 mice for per group and three cross-sections for per graft). B, The allografts adventitia of eGFP recipients harboring C57BL/6 BM cells at 2 weeks were digested and sorted for eGFP using flow cytometry. C, eGFP + cells in R were further stained with the following stem cell markers: stem cell antigen-1 (Sca-1), CD34, Flk1, and c-kit. Each experiment was repeated 5×.
This population of EGFP + cells in the adventitia expressed an early marker of differentiated SMCs during the early stage of TA, whereas the EGFP + cells in the neointima expressed a mature marker of SMCs during the advanced stage. Therefore, we used different stem cell markers to verify whether adventitial EGFP + cells were SMPCs. Flow cytometry analyses revealed that Sca-1 + cells were the dominant cell phenotype in adventitial EGFP ++ cells at 2 weeks after transplantation ( Figures 3B and  3C ). From our previous results, we determined that these population of EGFP ++ cells in the graft adventitia contained resident SMPCs. After massive BMDCs infiltrated in the grafts, the resident SMPCs quickly accumulated in the neointima. Thus, we postulated that the SMPCs might be recruited by the BMDCs.
SMPCs Differentiate Into SMLCs and Contribute to Neointima Hyperplasia
The EGFP mice harboring C57BL/6 BM cells received aorta transplantation to investigate the biological characteristics of SMPCs. Graft adventitia were digested using collagenase 2 weeks later, and the EGFP + cells were sorted using a flow cytometer and cultured in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum. Medial SMCs were cultured as a control group.
Graft adventitia EGFP + cells were similar to the medial SMCs in shape but exhibited greater proliferative ability than mature SMCs in primary culture ( Figure 4A ). In the primary passage, the majority of the cells were positive for Sca-1 and SM-22α but negative for SM-MHC ( Figure 4B ). Then the Sca-1 + cells were isolated from them using anti-Sca-1 immunomagnetic microbeads for further study, and these EGFP and Sca-1 double-positive cells were deemed as SMPCs. A few SMPCs spontaneously expressed SM-MHC after 3 to 5 passages. Most SMPCs could express SM-MHC after the platelet-derived growth factor receptor BB was added to the medium ( Figure 4C ).
The EGFP-labeled cells were mixed with 1% Matrigel and applied to the external side of the allografts during aorta transplantation to confirm the contribution of cultured SMPCs to neointimal hyperplasia in vivo. These EGFP + cells were also positive for Sca-1 and migrated across the media to the neointima 2 weeks after surgery, and these cells composed the majority of neointima cells 4 weeks later ( Figure VA -VD in the online-only Data Supplement).
BMDCs Accumulation in the Intima Induces the Migration of the SMPCs Through Chemokines In Vitro
The grafts of recipients harboring EGFP BM cells were harvested 2 weeks after transplantation, and the EGFP + cells were also sorted using a flow cytometer to investigate the relationship between BMDCs and SMPCs. We analyzed the migration of cultured SMPCs in response to BMDCs in a Boyden chamber. The SMPCs and BMDCs were seeded in the upper and lower chambers, respectively. Only medium was added to the lower chamber of the control group after the SMPCs were seeded in the upper chamber. The migration of SMPCs was greatly promoted by BMDCs compared with the control groups ( Figure VIA in the online-only Data Supplement).
We then investigated the underlying mechanism that promoted the migration of SMPCs. RT-PCR was used to determine the mRNA levels of 10 different chemokines, which have previously been reported to induce the migration of SMCs, in the BMDCs of the neointima. 23, 24 The BM cells of C57BL/6 mice were used as a control. Half of the measured chemokines were elevated, and the expression level of regulated upon activation normal T-cell expressed and secreted (RANTES) and MCP-1 were 5-fold higher than the control ( Table III in Therefore, we concluded that accumulating BMDCs in the neointima expressed key chemokines that could induce resident SMPC migration into the neointima.
MCP-1 Expression in BMDCs Is Significantly Regulated by miR-155
Cultured BM cells were transfected with miR-155 mimics and inhibitor to investigate the relationship between miR-155 and the 2 chemokines. Supernatants were collected 48 hours later, and the concentrations of RANTES and MCP-1 were measured using ELISA. It was found that the protein expression level of MCP-1 more closely responded to the expression of miR-155 ( Figure VIIA and VIIB in the online-only Data Supplement). Our results are consistent with the observations made by Nazari-Jahantigh et al, 25 who demonstrated that miR-155 directly repressed expression of B-cell leukemia/lymphoma 6 (BCL6) and promoted the expression of MCP-1 by macrophages in atherosclerotic lesions. We obtained similar results in vitro when the BCL6 and MCP-1 protein levels in BM cells were determined by Western blot ( Figure VIIC in the onlineonly Data Supplement). Then, we measured the mRNA levels of BCL6 and MCP-1 in the neointima of recipients harboring miR-155 +/+ and miR-155 −/− BM cells at 2 weeks after the transplantation. Our results demonstrated that miR-155 knockout in the BMDCs also promoted the expression of BCL6 and resulted in inhibition of MCP-1 in TA lesions ( Figure VIID in the online-only Data Supplement). To further investigate the relationship between MCP-1 and BMDCs in vivo, immunofluorescent double staining for MCP-1 and EGFP was performed in the recipients transplanted with EGFP bone marrows at 2 weeks, and most of the BMDCs were also positive for MCP-1 ( Figure VIII 
miR-155 Maintains the MCP-1 Concentration Gradient Between the Intima and Adventitia by Increasing BMDCs Accumulation in the Neointima and Promoting the Expression of MCP-1
Next, the relative levels of MCP-1 mRNA were measured in the neointima and adventitia in vivo using RT-PCR to identify the effects of the miR-155-MCP-1 axis in the pathogenesis of TA. We found a large concentration gradient of MCP-1 between the neointima and adventitia in the grafts of mice that received miR-155 +/+ BM transplants during the early stage; this gradient significantly decreased during the advanced stages. In contrast, the concentration gradient of MCP-1 was much lower in recipients harboring miR-155 −/− BM cells ( Figure 5A and 5B) .
Immunohistochemistry was used to identify CD68 + cells and to determine the expression of MCP-1 in the neointima and adventitia to further investigate the mechanism by which the MCP-1 concentration gradient was formed. The lesional content of CD68 + macrophages in the neointima was higher in recipients with miR-155 +/+ BM cells than in recipients with miR-155 −/− BM cells 2 weeks after surgery ( Figure 5C and 5D ). The MCP-1 was mainly expressed in neointima cells and some adventitia cells at 2 weeks after transplantation, which was similar to the distribution of CD 68-positive cells. When miR-155 was knockedout in BMDCs, the number of CD 68-and MCP-1-positive cells decreased simultaneously ( Figure 5E and 5F). Our results indicated that miR-155 maintains the MCP-1 concentration gradient by increasing the accumulation of BMDCs in the neointima and by promoting the expression of MCP-1.
miR-155 Promotes the Migration of SMPCs Through BMDCs but Does Not Directly Affect the Migration of SMPCs
BM cells transfected with miR-155 mimics or inhibitors were seeded in lower chambers of transwells to verify the role of miR-155 in the migration of SMPCs. BM cells transfected with scrambled miR-155 served as a control. BM cells transfected with miR-155 mimics resulted in greater cell migration. In contrast, the miR-155 inhibitor suppressed migration ( Figure 6A ). We also performed an alternative migration assay using SMPCs transfected with miR-155 mimics and inhibitors; no significant difference in migration was observed ( Figure 6B ). The differences in SMPC migration in response to miR-155 was alleviated when the BM cells were transfected with siBCL6 or when an anti-MCP-1 antibody was added to the lower chamber ( Figure 6C and 6D) . Thus, we confirmed that although miR-155 promoted the migration of SMPCs by regulating the MCP-1 released by BMDCs, miR-155 did not directly affect the migration of SMPCs.
Discussion
The role of BMDCs and resident progenitor stem cells in the pathogenesis of neointimal hyperplasia is controversial. 10,26-29 Our results may reconcile a few of these discrepancies. First, we confirmed that BM-derived inflammatory cells determined the degree of neointimal hyperplasia; however, BMDCs constituted a small proportion of cells in TA lesions in advanced stages, and these cells differentiated into inflammatory cells but not in SMLCs. We then demonstrated that resident SMPCs migrated into the intima and subsequently differentiated into SMLCs secondary to the accumulation of BMDCs in the intima. Furthermore, we showed that the miR-155-MCP-1 axis served as a link between BMDCs and the resident SMPCs.
In our study, miR-155 was highly expressed during the early and late stages of neointimal lesions, which suggests that miR-155 was elevated in BMDCs and SMLCs. Although the specific effect of miR-155 on SMLCs remains unclear, we found that miR-155 did not directly influence the migration of SMPCs. Several investigators have reported a relationship between miR-155 and inflammatory cells and that miR-155 is induced during the macrophage inflammatory response. 20, 30 Du et al 22 indicated that miR-155 deficiency results in decreased macrophage inflammation. Nazari-Jahantigh et al 25 reported that miR-155 promoted the expression of MCP-1 in macrophages during atherosclerosis, and Grudzinska et al 17 reported that MCP-1 was a potent chemokine for the migration of mesenchymal stem cells in an aorta transplantation model. 25 We hypothesized that the primary contribution of miR-155 in the pathogenesis of TA was to maintain the MCP-1 concentration gradient between the intima and adventitia through the BMDCs. Schepers et al 31 also reported that anti-MCP-1 therapy significantly attenuated the neointimal hyperplasia of vein grafts, which further supports our hypothesis. miR-155 exhibits many physiological functions and even plays a role in T-cell-mediated immune injury. Immunosuppressive therapies that target T cells prevent acute rejection; however, these therapies do not alleviate the progression of TA. 27 Intimal hyperplasia is an excessive healing response after immune or nonimmune injury, and the resultant accumulation of SMLCs and extracellular matrix is a progressive consolidation of the neointima. 24 Therefore, the functional role of miR-155 in acute rejection was not included in our study.
Recent studies have demonstrated that the adventitia is a connective tissue around blood vessels and a dynamic compartment for cells entering or departing the artery wall. 14 The adventitia harbors a population of Sca-1 + resident progenitor stem cells that respond to arterial injury. 19 However, no specific surface markers to identify SMPCs have been discovered, and the role of these vascular progenitors in the pathogenesis of TA is unclear. Our study identified a population of non-BMDCs that presented in the adventitia of grafts at an early stage. These cells emerged in the neointima with the development of TA and constituted the majority of neointima cells. These cells simultaneously expressed a stem cell surface marker and an early differentiated smooth muscle marker. Therefore, we postulated that perivascular progenitor cells likely represent an additional source of neointimal SMLCs.
This study used SM-22α as an early differentiating marker of SMPCs. SMCs express α-smooth muscle-actin from an early stage of development, but α-smooth muscle-actin is also expressed by a wide variety of non-SMC cell types. 10 SM-22α offers additional advantages as a differentiation marker because of its high specificity, small size, and high efficiency. 32 Tian et al 33 isolated a pure population of SMCs with less differentiated phenotypes from mouse embryonic stem cells and found that these cells expressed significantly more SM-22α than VSMCs but less SM-MHCs. SM-MHC expression gradually elevated when the SM-MHC-negative SMPCs migrated into the neointima. Xiao et al 34 demonstrated that collagen IV plays a functional role in the differentiation of Sca-1+progenitor cells. The extracellular matrix of the neointima lesion is rich in collagen IV, which may explain why SMPCs differentiate into SM-MHC-positive SMLCs after migrating to the neointima.
The potential source of these SMPCs includes the progenitors of the surrounding tissues and circulating progenitors. Chen et al 19 found resident progenitor cells near the vasa vasorum and suggested that the vasa vasorum served as a means of transport and as a reservoir of mobilized progenitor cells. Hagensen et al 29 used a double-transplantation technique to exclude the interference of circulating cells and reported that the flanking recipient vasculature contributed to neointima hyperplasia in TA lesions instead of circulating progenitor cells. Our study did not provide direct evidence to identify the source of SMPCs. We will further investigate the origin of these cells in subsequent research.
In summary, we demonstrated that the increased miR-155 expression in BMDCs played a key role in the process of TA, sustained the MCP-1 concentration gradient, and promoted the migration of adventitial SMPCs. The clinical efficacy of current strategies that only inhibit SMCs or T-cell proliferation is not satisfactory. 14 Our results may provide new perspectives for the prevention of the neointimal formation of TA.
